Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled 'Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)'.
Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring
- Thread starter Educator
- Start date